Isoln from Streptomyces achromogenes fermentation broth: Herr et al., Antibiot. Annu. 1959-1960, 236; Bergy et al., FR 1434920 (1966 to Upjohn), C.A. 65, 17661h (1966). Structure and synthesis: R. R. Herr et al., J. Am. Chem. Soc. 89, 4808 (1967); E. Hardegger et al., Helv. Chim. Acta 52, 2555 (1969); E. J. Hessler, H. K. Jahnke, J. Org. Chem. 35, 245 (1970); P. F. Wiley et al., ibid. 44, 9 (1979). Diabetogenic effect: Rakieten et al., Cancer Chemother. Rep. 29, 91 (May 1963). Antileukemic activity: Bhuyan et al., Cancer Chemother. Rep. Part 1 56, 709 (1972). Biosynthetic study: S. Singaram et al., J. Antibiot. 32, 379 (1979). Review and evaluation of studies of carcinogenicity in laboratory animals: IARC Monographs 4, 221-227 (1974). Review: B. Rudas, Arzneim.-Forsch. 22, 830-861 (1972); P. F. Wiley, Anticancer Agents Based on Natural Product Models, J. M. Cassidy, J. D. Douros, Eds. (Academic Press, New York, 1980) pp 167-200. Book: Streptozotocin: Fundamentals and Therapy, M. K. Agarwal, Ed. (Elsevier/North Holland Biomedical Press, New York, 1981) 309 pp. Review of pharmacology and clinical efficacy: R. B. Weiss et al., J. Org. Chem. 44, 9-16 (1978).
Antineoplastic.
Antineoplastic; Antibiotics and Analogs